Introduction-We characterized the association of 3 metabolic conditions -obesity, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) -with increased inflammation and subclinical atherosclerosis.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is an important condition with an estimated worldwide prevalence of 20% 1 . There is increasing recognition that NAFLD is associated with cardiovascular disease (CVD). Cross-sectional epidemiologic studies have shown NAFLD to be linked to a higher prevalence of CVD independent of traditional risk factors 2 . NAFLD has also been associated with an increased risk of CVD events in patients with type 2 diabetes independent of obesity, other metabolic syndrome components, and traditional risk factors 3 . Indeed, the most common cause of death among individuals with NAFLD is CVD 1 .
In addition to manifest CVD, NAFLD has been associated with increased inflammation [4] [5] [6] [7] and subclinical atherosclerosis [8] [9] [10] [11] [12] both of which are well known predictors of CVD in asymptomatic patients [13] [14] [15] [16] [17] [18] [19] . NAFLD has also been closely associated with obesity and metabolic syndrome -two conditions known to be associated with CVD, subclinical atherosclerosis, and systemic inflammation [20] [21] [22] [23] [24] . The associations of these metabolic conditions with inflammation and subclinical atherosclerosis have not been well characterized. As a result, some investigators have contended that NAFLD is an epiphenomenon as opposed to a mediator in the development of CVD 25 . The relationship between NAFLD, obesity, metabolic syndrome, and CVD is further complicated by the known ethnic differences in the prevalence of both NAFLD and metabolic risk factors 26 .
We hypothesized that NAFLD would be associated with high sensitivity C-reactive protein (hsCRP) as well as coronary artery calcium (CAC) independent of obesity and metabolic syndrome, and that this relationship would be similar across ethnic groups. Furthermore, we hypothesized that there would be a graded association between the number of these metabolic conditions present and the prevalence of high hsCRP and CAC. study was approved by the institutional review board of each site, and all participants gave written informed consent.
A total of 4,384 individuals had an adequate non-contrast cardiac CT imaging to diagnose fatty liver. Compared to those who were excluded for inadequate CT imaging, our population was in general older, more likely to be female and had a higher prevalence of obesity, diabetes and hypertension. Those with adequate imaging were also more likely to be black and Hispanic but less likely to be Chinese. We excluded 285 individuals for a history of heavy alcohol use (> 14 drinks/week for men, > 7 drinks/week for women), known cirrhosis, oral corticosteroid or amiodarone use. An additional 123 individuals were excluded for missing covariates. The final population consisted of 3,976 participants.
HsCRP Measurement
HsCRP was measured at the baseline examination using a particle-enhanced immunonepholometric assay on the BNII nephelometer (Dade-Behring, Inc., Deerfield, IL) 28 at the University of Vermont, Burlington, Vermont. We defined increased inflammation as hsCRP ≥2 mg/L 29 .
CAC Score Measurement
Details of the MESA scanning protocol have been reported previously 30 . All participants underwent CAC scoring using computed tomography (CT) as part of the baseline examination. CAC was measured with either a cardiac-gated electron-beam CT scanner (Chicago, Los Angeles, New York), or a multidetector CT (Baltimore, Forsyth County, St. Paul). Individuals were scanned twice, and mean CAC (Agaston) score was calculated and used for all analyses 31 . All images were interpreted at the MESA CT reading center (Los Angeles Biomedical Research Institute, Torrance CA). We defined subclinical atherosclerosis as CAC >0.
Liver Fat Assessment
Details of the liver fat measurement within MESA have been previously reported 26, 32 . Briefly, baseline cardiac CT scans were utilized to measure hepatic and splenic attenuation values (Hounsfield Units) using a region of interest of ≥ 100 mm 2 in area. Two regions in the right hepatic lobe and one in the spleen were measured. The liver/spleen (L/S) attenuation ratio was calculated using the mean of the hepatic measurements divided by the splenic attenuation value. NAFLD was defined as L/S attenuation ratio < 1.
Risk Factor Measurement
Information pertaining to demographics, medical history, cigarette smoking, and alcohol use was collected at the baseline visit using standardized questionnaires, as previously described 27 . Waist circumference was measured at the umbilicus. Body mass index (BMI) was calculated as weight in kilograms divided by height divided in meters squared. Using an automated sphygmomanometer (Critikon, Tampa, FL), systolic and diastolic blood pressure (SBP & DBP) were measured 3 times and the mean of the last two measurements was used. A central laboratory (Fairview-University Medical Center, Minneapolis, MN) measured levels of total and high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) after a 12-hour fast. Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation. Obesity was defined as BMI ≥ 30 kg/m 2 . Metabolic syndrome was defined by the American Heart Association/National Heart, Lung, and Blood Institute criteria as at least 3 of the following: waist circumference ≥102 cm for men and ≥88 cm for women; TG ≥ 150mg/dL or drug treatment for elevated TG; HDL-C < 40mg/dl for men and <50mg/dL for women or drug treatment for reduced HDL-C; SBP ≥130 mmHg or DBP ≥85 mmHg or drug treatment for hypertension; and fasting blood glucose level ≥ 100 mg/dL or drug treatment for elevated glucose 33 .
Statistical Analysis
We described baseline characteristics by presence or absence of NAFLD. We used logistic regression models to study the cross-sectional association between NAFLD and the outcomes of hsCRP ≥2 mg/L and CAC >0. The first model was adjusted for age, gender, and ethnicity as well as other CVD risk factors not included in the metabolic syndrome: smoking status, LDL-cholesterol, use of lipid-lowering medication, and level of education. In order to assess the strength of association for NAFLD independent of obesity and metabolic syndrome, a second logistic regression model was performed adjusting for obesity and components of the metabolic syndrome (each individual component coded as binary) in addition to the covariates used in model 1. These two logistic regression models were stratified by ethnicity and gender and estimates were calculated for each ethnicity or gender category. Formal multiplicative interaction testing was also performed for the ethnicity and gender variables with NAFLD. As a sensitivity analysis we adjusted for overweight rather than obesity and obtained unchanged results.
In order to assess a possible gradient-response, logistic regression (Model 1) was used to examine the association of a stepwise increase in the number (0-3) of metabolic conditions (NAFLD, obesity, metabolic syndrome) with increased inflammation and subclinical atherosclerosis. We also calculated the p-value for linear trend of the prevalence odds ratios.
All analyses were performed using STATA version 13.1 (Stata Corp, College Station, Texas).
Results
There were 670 (16.9%) individuals with NAFLD. Baseline characteristics according to presence/absence of NAFLD are shown in Table 1 . Mean age differed slightly, 61 (± 9.6) years for those with NAFLD and 63 (± 10.5) years for those without. Gender distribution was similar in each group (46% male). The ethnic makeup of the two groups differed significantly, with a predominance of Hispanics in the NAFLD group. Individuals with NAFLD were more likely to be obese and meet criteria for metabolic syndrome. The crude prevalence of hsCRP ≥2 mg/L and CAC >0 was greater in those with NAFLD compared to those without (63% vs. 46%) and (54% vs. 50%) respectively. Model 1). In analysis stratified by ethnicity, the association between NAFLD and increased inflammation remained significant across all ethnic groups. Additionally, when the population was stratified by gender, the association remained significant for men and women. Notably, the association between NAFLD and increased inflammation was stronger in women and was confirmed by formal interaction testing (p = 0.006). There was no significant interaction according to ethnicity (p=0.14).
Additional analyses were conducted further adjusting for obesity and components of the metabolic syndrome to test for a true independent effect of NAFLD on increased inflammation ( Table 2 , Model 2). The overall association remained significant with a 1.5 fold greater odds of hsCRP ≥2 mg/L [OR= 1.47, 95% CI (1.20-1.79)]. When this fully adjusted model was stratified by ethnicity, the association remained significant for whites only. Formal interaction testing for ethnicity was nonsignificant (p= 0.48). In genderspecific analysis, the association was only significant for women. Formal interaction testing for gender was again significant (p= 0.006).
NAFLD and subclinical atherosclerosis
The presence of NAFLD was also associated with an increased prevalence of CAC. Multivariable adjusted prevalence odds ratios show a 1.6-fold greater odds of CAC >0 [OR= 1.63, 95% CI (1.34-1.98)] ( Table 3 , Model 1). In ethnicity-stratified analysis this association remained significant among white and Hispanic individuals. In gender-specific analysis, both men and women with NAFLD had an increased prevalence of CAC. Formal interaction testing for both ethnicity and gender were non-significant (p=0.21 and p=0.83 respectively).
When the model was further adjusted for obesity and components of metabolic syndrome, the overall association remained significant with a 1.4-fold greater odds of CAC >0 [OR= 1.37, 95% CI (1.11-1.68)] ( Table 3 , Model 2). In analysis stratified by ethnicity, the association remained significant only for Hispanic individuals. In gender-specific analysis, the association was only significant for women. Formal interaction testing for ethnicity and gender were non-significant (p=0.18 and p=0.85 respectively). Figure 1 demonstrates the gradient response relationship between the number of metabolic conditions (obesity, metabolic syndrome, and NAFLD) with both inflammation and subclinical atherosclerosis. There was a nearly constant absolute increase in prevalence odds ratios, suggesting a possible graded association. Compared to absence of these metabolic conditions, the presence of 1, 2 and all 3 of these conditions was associated with a prevalence odds ratios of [ 
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Discussion
The results of our cross-sectional analysis from this multi-ethnic cohort demonstrate that the presence of NAFLD is associated with systemic inflammation and subclinical atherosclerosis. This relationship remained significant after adjusting for traditional risk factors, obesity, and metabolic syndrome. We have also shown that there is a gradient response relationship with increasing number of these metabolic conditions suggesting a possible graded relationship of obesity, metabolic syndrome, and NAFLD on increased systemic inflammation and subclinical atherosclerosis.
Several prior studies have evaluated the independent association between NAFLD and inflammation as well as the relationship between NAFLD and subclinical atherosclerosis. The data demonstrating the positive association between NAFLD and increased inflammation has been fairly consistent [4] [5] [6] [7] . In contrast, the data evaluating the association between NAFLD and CAC has been mixed. Several prior studies have demonstrated an increased burden of CAC among individuals with NAFLD independent of traditional risk factors and measures of abdominal adiposity [8] [9] [10] [11] [12] , whereas others have not 34, 35 . A previous subgroup analysis from the MESA cohort evaluated the association between NAFLD and CAC in 398 black and white individuals from a single field center in North Carolina 34 . In this group, NAFLD was not associated with CAC. The small population size from a single center likely accounts for the difference in results from our current analysis. Furthermore, the ethnic makeup of the smaller cohort consisted of black and white individuals as opposed to the more diverse MESA cohort. The recently published analysis from the Coronary Artery Risk Development in Young Adults Study (CARDIA) evaluated the association between NAFLD and CAC in 2,424 white and black individuals with a mean age of 50 years. In this cohort, there was no significant association between NAFLD and CAC after adjustment for measures of adiposity 35 . The younger population may explain the difference in results compared with our analysis as well as other studies in which the mean age of the populations was generally higher.
A key strength of this analysis is the ethnic diversity of the MESA cohort. The majority of prior studies evaluating the impact of NAFLD on inflammation as well as subclinical atherosclerosis have been performed in ethnically homogeneous populations. Given the known ethnic variations in prevalence of NAFLD, it is important to evaluate the impact of NAFLD in a multi-ethnic cohort. In the current analysis, when the population was stratified by ethnicity, the multivariable-adjusted association between NAFLD and increased inflammation only remained significant among whites, whereas the relationship between NAFLD and CAC only remained significant among Hispanic individuals. Importantly however, formal multiplicative interaction testing between NAFLD and ethnicity was nonsignificant for increased inflammation or subclinical atherosclerosis, suggesting that the ethnic variation in strength of association may have been due to chance, possibly in the setting of the limited sample size of the ethnic subgroups.
This study has limitations that warrant acknowledgement. The use of CT is not as specific for the diagnosis of fatty liver as histology or magnetic resonance spectroscopy 36 . However, CT has been used in several prior epidemiologic cohorts for the diagnosis of fatty liver and has compared reasonably well to other imaging modalities 37 . Additionally, the crosssectional nature of this analysis is an important limitation that precludes conclusions regarding temporality. Furthermore, we used categorical risk factor data rather than continuous variables because of the binary method in which metabolic syndrome is defined.
In conclusion, our results suggest that NAFLD is associated with both increased inflammation and subclinical atherosclerosis, independent of traditional risk factors, obesity and metabolic syndrome. Additionally, with an increasing burden of the three closely-linked metabolic conditions (NAFLD, obesity, and metabolic syndrome) there is a stepwise increase in the prevalence of increased inflammation and subclinical atherosclerosis, suggesting a graded association. Further research looking at the longitudinal effects of NAFLD may help discern whether this is a marker or mediator of disease.
• NAFLD was associated with inflammation and subclinical atherosclerosis independent of obesity and metabolic syndrome
• Different results were seen when stratifying by gender and race
• With increasing burden of NAFLD, obesity and metabolic syndrome, there is a stepwise increase in the prevalence of inflammation and subclinical atherosclerosis Table 3 Prevalence odds ratios (95% CI) for the association between NAFLD and CAC >0 N CAC >0/ N Overall
Model 1 Model 2
Overall 2,002/3 ,976 1.63 (1.34-1.98) 1.37 (1.11-1.68 
